Bank of Human Leukocytes From COVID-19 Convalescent Donors With an Anti-SARS-CoV-2 Cellular Immunity
Recruiting now · Not applicable
Conditions studied: COVID-19
In brief
The SARS-CoV-2 identified in China in January 2020 is the cause of an unprecedented pandemic. The SARS-CoV-2 and each viral variant are responsible of a respiratory infectious disease, which can be asymptomatic. Nevertheless, a part of infected patients will experiment serious forms associated with a high mortality rate. Most serious forms present with lymphopenia and a functional exhaustion of speicifci T lymphocytes. Several studies showed that these quantitative and qualitative lymphocyte abnormalities are associated with unfavourable patients' outcome. The investigators hypothesized that the use of anti-viral T lymphocytes from convalescent COVID 19 donors could be helpful to improve the prognosis of COVID-19 serious forms. This study aims to demonstrate the feasibility of setting up a biobank that could allow the preservation and production of a cellular immunotherapy specific to SARS-CoV-2.
Key facts
- Study ID
- NCT05458440
- Run by
- Central Hospital, Nancy, France
- People needed
- 32
- Starts
- 2022-09-01
- Expected to finish
- 2025-12-15
- Last updated by the study team
- 2025-08-08
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient hospitalised for proved SARS-CoV-2 infection in the infectious disease unit of the Nancy University Hospital who received a comprehensive information about the study, and accepted to participate
- Patient who has an active cellular immunity against SARS-CoV-2 (biological definition: Elispot IFNgamma : > 50 SFC/106 PBMC)
You may not qualify if…
- Patient hospitalised in Intensive car unit
- Patient with haemoglobin < 10 g/dl
- Patient who take hypertension medication
- Patient with cardiovascular history: Valvulopathy, conduction rythm disorders, arterial vascular insufficiency, congenital anomalies
- Patient with auto-immune disease
- Patient with medical history of solid or hematopoietic graft
- Patient with active malignant disease (haematological or neoplasm) or considered in remission since less than 2 years
- Patient with psychiatric disorders
- Patient subject to a legal protection measure.
- Patient with proved infectious disease
- Asplenic patient
- Pregnant or breastfeeding woman
- Woman without contraception
Where it is running
- CHRU-Nancy - Hopitaux de Brabois - Batiment Philippe Canton — Vandœuvre-lès-Nancy, Lorraine, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.